Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

TARRYTOWN, N.Y. and BERLIN, April 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO).  The positive results from the GALILEO study confirm the results of the similarly designed Phase 3 COPERNICUS study that were announced in December 2010.

In GALILEO, the primary endpoint at week 24 was achieved: 60.2 percent of patients receiving monthly VEGF Trap-Eye 2 milligrams (mg) gained at least 15 letters of vision from baseline, compared to 22.1 percent of patients receiving sham injections (p<0.0001).  The key secondary endpoint of the study was also met: patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 18 letters of vision compared to a mean gain of 3.3 letters with sham injections (p<0.0001).

"After reporting positive results from the VIEW 1 and VIEW 2 Phase 3 studies for the treatment of the neovascular form of age-related macular degeneration, or wet AMD, we are very pleased to now also have two positive Phase 3 trials with VEGF Trap-Eye in central retinal vein occlusion," said Kemal Malik, M.D., Head of Global Development and member of the Bayer HealthCare Executive Committee.

"With two Phase 3 trials showing impressive improvement in vision relative to control, VEGF Trap-Eye has the potential to provide patients and physicians a new treatment option for central retinal vein occlusion," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories.

As in the COPERNICUS trial, VEGF Trap-Eye was generally well tolerated in the GALILEO study and the most common adverse events were those typically associated with intravitreal injections or the underlying
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
... SPEX ) reported that patient recruitment for its Phase ... Naturlose(R), has begun in,India. Expectations for India are to ... the pivotal Phase 3 trial. "Now that enrollment efforts,are ... trial will be completed,on schedule as reported during the ...
... only participant in Texas for TFAS spinal implant, PLANO, ... again in motion preserving technology by continuing to advance,spinal device ... (TFAS)(R)., Dr. Barton Sachs of Texas Back Institute performed ... Texas resident was one of,the first 40 people worldwide to ...
Cached Medicine Technology:Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2Texas Back Institute Leads Way in New Facet Joint Clinical Trial 2
(Date:3/30/2015)... 2015 Bunion Bootie is a ... for family members, friends...and yourself and save. For a limited ... an additional 10%, on top of discounts already offered when ... at checkout. The more Bunion Booties purchased, the more money ... bunion pads, Bunion Bootie can be worn comfortably and easily ...
(Date:3/29/2015)... March 29, 2015 Women’s Excellence ... treatment. Secondary to their location in Birmingham, they ... option. They continue to be affiliated with Crittenton, ... , Menopause is a normal condition that all women ... any of the changes a woman goes through either ...
(Date:3/29/2015)... The Claudia Cohen Research Foundation ... announce today that Dr. Beth Y. Karlan has been ... Research Foundation Prize for Outstanding Gynecologic Researcher. The $50,000 ... Oncology 46th Annual Meeting on Women's Cancer in Chicago. ... Cancer Program at the Samuel Oschin Comprehensive Cancer Institute ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Menopause 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3
... hay fever symptoms could be reduced by 60% with the ... in Baltimore. ,Dr. Peter Socrates Creticos, medical director ... Johns Hopkins University School of Medicine and his team tested ... ,The study was conducted on 25 volunteers with ...
... health shops to overcome depression only one actually has any ... have said that St John's Wort is the only alternative ... others including gingko biloba, ginseng, cat's claw, royal jelly and ... serious drug interactions". ,The experts, Joyce Reed, a ...
... a dozen top universities on Tuesday by the government ... hasten scientific discoveries towards better health care thereby trying ... ,This idea came about because of the increased specialization ... ever for scientists from different fields to share the ...
... the All India Institute of Medical Sciences (AIIMS), including ... postponed its medical students' semester examination scheduled for later ... their hostel rooms after a seventh semester student died ... virus include medical students, resident doctors and other hospital ...
... and biotech major Wockhardt Limited announced on Tuesday ... $150 million that will help it broaden its presence ... a larger footprint in Europe spread over Britain, Ireland ... ,'European business will now exceed $200 million, accounting for ...
... tuberculosis that caused a major outbreak in a British school ... has surfaced again, directing its destruction on a specific ethnic ... a study to examine the potency of the 2001 outbreak. ... disease with the BCG vaccine. ,The severe strain, ...
Cached Medicine News:Health News:DNA vaccine for ragweed allergies 2Health News:Unscientific Depression Drugs aplenty in Health Stores 2Health News:NIH Funds the Development of National Consortium of Universities 2
... Used for temporary ... ureteropelvic junction to the ... peel-open packages. Intended for ... evaluation is advised; C-Flex® ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: